January 1, 1981Thrombosis and Haemostasis
Platelet Activation in Myeloproliferative Disorders
Authors
Discussion
Loading...
Member takes
Implication
Observational study reveals true in vivo platelet activation in only one-third of myeloproliferative disorder cases, suggesting more selective use of antiaggregating therapy.
Key Points
- Determine whether elevated plasma beta-thromboglobulin and platelet factor 4 in patients with myeloproliferative disorders reflect true in vivo platelet activation or merely elevated platelet counts.
- Measured plasma beta-thromboglobulin (beta-TG) and platelet factor four (PF4) both as absolute concentrations and as ratios relative to platelet count in 69 patients with myeloproliferative disorders.
- Elevated absolute levels were observed in 74% of patients for beta-TG and 68% of patients for PF4.
- High marker levels were solely attributable to high platelet counts with normal marker-to-platelet ratios in 34.7% of beta-TG cases and 31.9% of PF4 cases, confirming true in vivo platelet activation in only approximately one-third of patients.
Cite This Study
Cortelazzo et al. (1981) studied this question.